Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PEPD | P12955 | 3/20 | 0.56 |
| ▸ | XPNPEP1 | Q9NQW7 | 2/20 | 0.56 |
| ▸ | DPP4 | P27487 | 9/20 | 0.56 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.56 |
| ▸ | FAP | Q12884 | 3/20 | 0.56 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.56 |
| ▸ | PREP | P48147 | 3/20 | 0.56 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.56 |
| ▸ | PITRM1 | Q5JRX3 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 3/20 | 0.42 |
| ▸ | REN | P00797 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1506214 | 1.00 | PEPD (0.56) | PEPDXPNPEP1DPP4DPP7FAP | |
| SCHEMBL1506217 | 1.00 | PEPD (0.56) | PEPDXPNPEP1DPP4DPP7FAP | |
| Hydrochloric Acid SCHEMBL22798316 | 0.98 | PEPD (0.55) | PEPDXPNPEP1DPP4DPP7FAP | |
| Hydrochloric Acid SCHEMBL22798315 | 0.98 | PEPD (0.55) | PEPDXPNPEP1DPP4DPP7FAP | |
| SCHEMBL18621661 | 0.95 | PEPD (0.52) | PEPDXPNPEP1DPP4DPP7FAP | |
| SCHEMBL18620684 | 0.91 | DPP4 (0.54) | PEPDXPNPEP1DPP4DPP7FAP | |
| Hydrochloric Acid SCHEMBL11569047 | 0.88 | PEPD (0.57) | PEPDXPNPEP1DPP4DPP7FAP | |
| SCHEMBL28594897 | 0.88 | PEPD (0.59) | PEPDXPNPEP1DPP4DPP7FAP | |
| SCHEMBL9532959 | 0.88 | PEPD (0.59) | PEPDXPNPEP1DPP4DPP7FAP | |
| SCHEMBL6374536 | 0.88 | PEPD (0.59) | PEPDXPNPEP1DPP4DPP7FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3341007-B1 | MALT1 INHIBITORS AND USES THEREOF | UNIV CORNELL (US) | 2020-12-23 | — | — | EP | disclosed |
| US-10711036-B2 | MALT1 inhibitors and uses thereof | CORNELL UNIVERSITY (US) | 2020-07-14 | — | — | US | disclosed |
| WO-2017040304-A1 | MALT1 INHIBITORS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2017-03-09 | — | — | WO | disclosed |
| WO-2008033389-A2 | MACROCYCLIC HCV INHIBITORS AND THEIR USES | NOVARTIS AG (CH) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10711036-B2 | MALT1 inhibitors and uses thereof | MALT1, BCL3, BCL6 | PEPD 2469/4885XPNPEP1 1568/4885DPP4 2242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.